Scientists at St. Jude Children’s Research Hospital have found a previously overlooked mutation in a subtype of pediatric leukemia that has implications for identifying high-risk patients.
Scientists at St. Jude Children’s Research Hospital and the Cancer Research Center in Spain blocked development of acute lymphoblastic leukemia in mice with a genetic mutation that increases the risk of childhood cancer.
Diamond jubilee events planned nationwide for supporters to honor St. Jude visionaries, recognize expanding global impact of scientific, medical achievements.
Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer.
The Global Platform for Access to Childhood Cancer Medicines, the first of its kind, will provide an uninterrupted supply of quality-assured childhood cancer medicines to low- and middle-income countries. St. Jude is making a six-year, $200 million investment to launch the platform, which will provide medicines at no cost to countries participating in the pilot phase. This is the largest financial commitment for a global effort in childhood cancer medicines to date.
St. Jude Children’s Research Hospital phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
The thirteen scientists were named to the 2021 list of Highly Cited Researchers by the Institute for Scientific Information at Clarivate, reflecting the international reach of St. Jude research.
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
Following FDA authorization of the COVID-19 vaccine for 5- to 11-year-olds, Together by St. Jude releases a free coloring book that educates children on COVID-19 vaccines.
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
Together by St. Jude announces plans to launch in seven new languages, offering trustworthy medical information about pediatric cancer and shared stories of hope to families around the world
The chair of Pharmaceutical Sciences at St. Jude Children's Research Hospital will receive two top science honors from the American College of Clinical Pharmacy at its annual meeting. It is highly unusual for both to be presented to the same person in the same year.
Rosalie, a 60-pound golden retriever, joins St. Jude as a facility dog in the Staff Resilience Center dedicated to supporting employees.
Findings from St. Jude Children’s Research Hospital show how control of transcription factors by a common tumor suppressor gene may provide a therapeutic opportunity in a type of childhood cancer.
St. Jude Children’s Research Hospital scientists have revealed a previously unknown role for CTCF, a pivotal transcription regulator linked to cancer.
St. Jude Children’s Research Hospital scientists detail how inflammasomes act as integral components of mega-cell death complexes called PANoptosomes for host defense in live viral and bacterial infections.
NCI-designated cancer centers, AACI members and other cancer centers and medical groups endorse HPV vaccination and cancer screening to eliminate cancers caused by the virus.
Scientists from St. Jude Children’s Research Hospital and the International Society of Paediatric Oncology report results from the Global Registry of COVID-19 and Childhood Cancer.
St. Jude Children’s Research Hospital scientists have created a model of the rare pediatric eye cancer that more closely mimics the biology of patient tumors.
Tennessee health care providers, public health professionals and community stakeholders today issued an urgent call to action to protect Tennessee children from vaccine-preventable diseases.
St. Jude scientist Vibhor Mishra, Ph.D., is homing in on the location where important processes in gene regulation occur, and where single-stranded transcripts are converted into double-stranded RNAs (dsRNAs).
Results from a large phase 3 noninferiority clinical trial definitively showed that vincristine and dexamethasone pulses can be eliminated in patients with low-risk disease. The findings were published today in The Lancet Oncology.
St. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
A collaboration led by St. Jude Children’s Research Hospital, Shanghai Children’s Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse.
St. Jude Children’s Research Hospital scientists have shown that frailty contributes to neurocognitive decline in young adult survivors of childhood cancer.
William L. “Bill” Greene, PharmD, chief pharmaceutical officer, to receive the 2021 Shelby Rhinehart Public Service Lifetime Achievement Award.
Scientists from St. Jude Children's Research Hospital have proposed a new method for designing phase II clinical trials and have created a corresponding software to implement the approach.
A metabolic control pathway that regulates T follicular helper cells offers targets for drugs to stimulate the adaptive immune response.
St. Jude Children’s Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment.
A new study shows that colleges students are experiencing significant grief reactions in response to the COVID-19 pandemic.
Erica Sirrine, PhD, a grief and bereavement expert with years of building social work programs in academia, will direct a growing program at St. Jude Children's Research Hospital.
St. Jude immunologists are researching how effector and killer T cells can be controlled to destroy cancer cells that resist treatment.
The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention.
St. Jude retinoblastoma researchers studied how survivors fared years later at home and at school.
St. Jude Children’s Research Hospital scientists have developed a highly efficient method to address a major challenge in biology—identifying the genetic ‘switches’ that regulate gene expression.
St. Jude Children’s Research Hospital COVID-19 screening and vaccination program for employees offers early evidence that vaccine protects against asymptomatic infection, which has fueled the pandemic.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
Martine Roussel, Ph.D., a molecular oncologist at St. Jude Children's Research Hospital, has been elected to the 2021 Class of Fellows of the American Association for Cancer Research.
How do different parts of the body communicate? Scientists at St. Jude are studying how signals sent from skeletal muscle affect the brain.
Scientists at St. Jude Children’s Research Hospital are learning more about what the molecular groups of a rare pediatric brain tumor mean for clinical care.
In the spirit of growing scientific collaboration, grants will provide support for four projects across 15 research institutions using cutting-edge technology to address crucial issues in pediatric cancer research
St. Jude is dedicating staff and resources to focus on the prevention of human papillomavirus (HPV)-related cancers around the world through HPV vaccine awareness programming.
Childhood cancer and its treatment can result in cognitive struggles. St. Jude scientists are studying the risk factors.
Discovery of a metabolic pathways that inhibit memory T cell production has potential for enhancing the immune system’s ability to fight infections and cancers.
St. Jude Children’s Research Hospital has discovered a mechanism that tumors use to switch on protective regulatory T cells, raising the potential for drug treatments that render tumors more vulnerable to cancer immunotherapy.
Research from scientists at St. Jude Children’s Research Hospital found mutations up to two years before cancer developed, showing an opportunity for early interventions.
A pair of research papers from St. Jude Children’s Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
Scientists at St. Jude Children’s Research Hospital have identified genetic variants in African American childhood cancer survivors that have implications for up-front care and long-term surveillance.
Scientists at St. Jude Children’s Research Hospital have shed light on the mechanisms that underlie how Aspergillus fumigatus activates the inflammasome, with implications for therapeutic development.
Sara Federico, MD, received the NCI award for substantial impact in the field of childhood solid tumors through the development and conduct of clinical trials
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
